继续和取消β阻塞剂和心肌梗塞后的结果,保持左心室功能
Michael H Chiu1, Yuan Dong2, Nowell Fine3
1Libin Cardiovascular Institute, Department of Cardiac Sciences University of Calgary, Calgary, Alberta, Canada; Department of Critical Care Medicine, University of Calgary, Calgary, Alberta, Canada.
JACC. Advances
|May 23, 2025
概括
在急性心肌梗塞 (AMI) 后早期停止服用β阻塞剂的患者中,射分数保留并没有增加复合结局. 然而,早期停止β-阻断剂与更高的复发性AMI和重复血管化的风险有关.
科学领域:
- 心脏病学 心脏病学
- 临床研究 临床研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 经过急性心肌梗塞 (AMI) 后的β-阻断剂 (BB) 治疗与当代治疗的确定的作用需要进一步澄清.
- 调查早期停止BB治疗对患者结果的影响对于完善后AMI护理指南至关重要.
研究的目的:
- 评估急性心肌梗塞 (AMI) 后患者早期停止服用β-阻断剂 (BB) 与临床结果之间的关联.
- 这项回顾性队列研究评估了在出院后180天内停止BB处方是否会影响重大心血管不良事件.
主要方法:
- 一项回顾性队列研究分析了2008-2017年间的链接注册表和行政数据.
- 包括的患者在AMI后存活了≥180天,有新的BB处方,并保持左心室喷射率 (LVEF) ≥50%.
- 考克斯的比例危险模型评估了早期停药和复发性AMI,再血管化或5年内死亡的复合关系.
主要成果:
- 在4768名患者中,24.2%的人在180天内停止了BBs.
- 早期停止BB治疗与复合结局 (HR:1.09) 或所有原因死亡率 (HR:1.04) 没有显著的关联.
- 然而,早期的BB停止与复发性AMI和重复心肌再血管化的风险增加有关.
结论:
- 在维护LVEF的AMI患者中,早期停止BB治疗 (≤180天) 并没有增加综合结局的风险,包括死亡,复发性AMI或再血管.
- 然而,早期的BB停止与更高的复发性AMI发病率和需要重复的再血管化程序有关.
相关概念视频
01:22Heart Failure Drugs: β-Blockers
322
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
421
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
421
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
544
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
544
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
719
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
719
01:28Antihypertensive Drugs: Types of β-Blockers
604
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
604
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404